On the New Case Count

Ebola has an incubation period of about one and a half weeks. Transmission this week will appear in the case count late next week or in early June; the cases reported this week were set in motion weeks ago. The jump from 246 suspected cases at declaration to 513 three days later results from case finding in the affected health zones. Suspected cases are identified by clinical and epidemiological criteria, not by laboratory testing. The surge reflects field teams and retrospective record review uncovering cases that had previously gone unreported. Weeks of silent transmission compounded, then become visible all at once. Even 246 cases at the time of declaration implied that there had been multiple generations of uncontrolled spread. The new numbers are that hidden wave now becoming countable.

Laboratory capacity is the next bottleneck. The ratio worth tracking is confirmed to suspected, currently about 1 in 15, which indexes how quickly the lab system is catching up to the field. The trajectory of new cases in the next few weeks will reveal whether contact tracing and behavior change are bending the curve. If the slope does not flatten by then, the response will need a different theory.

On the American Case

Dr. Peter Stafford, a board-certified surgeon working with the medical-missions group Serge, tested positive for the Bundibugyo strain on May 18 after operating at Nyankunde Hospital near Bunia. He has been evacuated to Germany. Two colleagues at Serge, Dr. Rebekah Stafford and Dr. Patrick LaRochelle, are being monitored. The CDC has said it is helping a small number of additional Americans leave the region.

The case has drawn American attention because it crossed a border. The underlying fact, that clinicians in this outbreak face Ebola with PPE and infection control and little else, was already visible in the data. Four healthcare workers had died at Mongbwalu General Referral Hospital within four days before Stafford was diagnosed. Healthcare workers are the canary in almost every Ebola outbreak. They are also the response. Clinician attrition therefore degrades the very system that is needed to contain the virus.

On Interventions

A standard framing of this outbreak in the news media has been “no vaccine, no treatment.” For licensed products this is correct, and the biomedical pipeline against Bundibugyo is thinner than the one available for recent Zaire Ebola outbreaks. MBP134, a two-antibody cocktail developed by Mapp Biopharmaceutical with BARDA backing, rescued five of six nonhuman primates in a 2019 Bundibugyo challenge study and was deployed under compassionate use during Uganda’s 2022 Sudan virus outbreak. WHO is preparing trials of MBP134 and remdesivir pending DRC and Uganda regulatory sign-off. Africa CDC is weighing off-label Ervebo despite uncertain cross-protection. Thomas Geisbert, a virologist at the University of Texas Medical Branch, estimates Ervebo would be roughly 50 percent effective against Bundibugyo and described its likely cross-protection as “kind of a coin flip.”

Biomedical countermeasures are one part of an Ebola response. The workhorses are non-pharmaceutical. Safe burial protocols interrupt funeral transmission. Infection prevention and control in healthcare facilities prevents nosocomial amplification. Contact tracing identifies exposed individuals before they become infectious, and rapid isolation removes cases from circulation. The 2014 West Africa epidemic, the largest in history, was eventually bent down by this architecture. The Zaire vaccines and therapeutics that have become available since are adjuncts to it.

On the PHEIC

A Public Health Emergency of International Concern (PHEIC) is both a signal and a tool. As a signal, it is WHO’s highest formal alert. It communicates risk to member states, mobilizes political attention, and frames the international response. As a tool, it triggers a specific set of obligations and resource flows under the International Health Regulations: member states must report on the public health measures they are taking, WHO is authorized to issue temporary recommendations that can include travel and trade measures, the Emergency Committee continues to convene on a defined cadence, and the Contingency Fund for Emergencies is unlocked. The mechanism has been invoked eight times in twenty years, for H1N1 (2009), polio (2014), Ebola in West Africa (2014), Zika (2016), Ebola in Kivu (2019), COVID-19 (2020), mpox (2022), and mpox again for clade I (2024).

The track record is mixed. The 2014 West Africa Ebola PHEIC is generally credited with mobilizing the international response that eventually bent that outbreak’s curve, though it came months too late to prevent thousands of deaths. The 2020 COVID-19 PHEIC was followed by what the Independent Panel for Pandemic Preparedness and Response later called a “lost month” of inadequate national response.

For this outbreak, WHO has recommended against international travel or trade restrictions, stating that “such measures are usually implemented out of fear and have no basis in science.” The United States has nonetheless imposed a Title 42 order that bans non-US citizens from entering for 30 days if they have been in DRC, South Sudan, or Uganda in the previous three weeks. The CDC has separately placed travel to DRC under a Level 4 advisory.

On Spatial Spread

The Kinshasa result reflects a system that worked at distance but failed at source. Suspected cases that reached the national reference laboratory could be tested and resolved; suspected cases in Ituri were screened on the GeneXpert field platform, which is blind to Bundibugyo and returned false negatives for three weeks.

The outbreak has now spread well beyond Ituri. WHO has confirmed two cases in Uganda, including one fatal in Kampala. Uganda’s central laboratory has therefore demonstrated capacity to identify Bundibugyo. The DRC Health Ministry reports suspected cases under investigation in Goma, a North Kivu transit hub, and in Butembo. Less than two hundred kilometers separate Bunia from the Uganda border.